TWI649084B - 用於阿茲海默症之鼻內治療的具有生長因子之組成物之用途 - Google Patents
用於阿茲海默症之鼻內治療的具有生長因子之組成物之用途 Download PDFInfo
- Publication number
- TWI649084B TWI649084B TW102125858A TW102125858A TWI649084B TW I649084 B TWI649084 B TW I649084B TW 102125858 A TW102125858 A TW 102125858A TW 102125858 A TW102125858 A TW 102125858A TW I649084 B TWI649084 B TW I649084B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- growth factor
- plasma
- blood
- disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000003102 growth factor Substances 0.000 title claims abstract description 39
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 4
- 238000011282 treatment Methods 0.000 title abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 43
- 210000004369 blood Anatomy 0.000 claims abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 34
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 29
- 210000002381 plasma Anatomy 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 25
- 210000003169 central nervous system Anatomy 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 15
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 25
- 238000000034 method Methods 0.000 description 16
- 230000004770 neurodegeneration Effects 0.000 description 14
- 208000015122 neurodegenerative disease Diseases 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 229960000182 blood factors Drugs 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 210000001947 dentate gyrus Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000000196 olfactory nerve Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001032 spinal nerve Anatomy 0.000 description 3
- 210000004500 stellate cell Anatomy 0.000 description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- -1 PDGF Proteins 0.000 description 2
- 101150089079 PS1 gene Proteins 0.000 description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 101150031224 app gene Proteins 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000007723 transport mechanism Effects 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000007052 brain toxicity Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 231100000976 cerebrotoxicity Toxicity 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000008655 medium-term memory Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 238000000678 plasma activation Methods 0.000 description 1
- 108010088880 plasmagel Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201200810 | 2012-08-09 | ||
| ES201200810A ES2442242B1 (es) | 2012-08-09 | 2012-08-09 | Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201408310A TW201408310A (zh) | 2014-03-01 |
| TWI649084B true TWI649084B (zh) | 2019-02-01 |
Family
ID=49111229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102125858A TWI649084B (zh) | 2012-08-09 | 2013-07-19 | 用於阿茲海默症之鼻內治療的具有生長因子之組成物之用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20140044795A1 (enExample) |
| EP (1) | EP2883569B1 (enExample) |
| JP (1) | JP6339568B2 (enExample) |
| KR (1) | KR102149162B1 (enExample) |
| CN (1) | CN104519961A (enExample) |
| AR (1) | AR092086A1 (enExample) |
| BR (1) | BR112015002760A2 (enExample) |
| CA (1) | CA2881075A1 (enExample) |
| CL (1) | CL2014003510A1 (enExample) |
| CO (1) | CO7170177A2 (enExample) |
| ES (2) | ES2442242B1 (enExample) |
| IN (1) | IN2014MN02675A (enExample) |
| MX (1) | MX357828B (enExample) |
| PE (1) | PE20150616A1 (enExample) |
| RU (1) | RU2696497C2 (enExample) |
| TW (1) | TWI649084B (enExample) |
| WO (1) | WO2014023860A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2016003282A1 (es) | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569204B1 (en) * | 1999-01-26 | 2003-05-27 | Eduardo Anitua Aldecoa | Bone tissue regenerating composition |
| US20090035382A1 (en) * | 2007-08-02 | 2009-02-05 | Biotechnology Institute, I Masd, S.L. | Method and compound for the treatment of articular diseases or articular pain, or for the treatment of skin for aesthetic or other purposes, and the method of preparation of the compound |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1137401B1 (en) * | 1998-12-09 | 2005-11-23 | Chiron Corporation | Administration of neurotrophic agents to the central nervous system |
| US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
| US7608258B2 (en) * | 2002-04-13 | 2009-10-27 | Allan Mishra | Method for treatment of tendinosis using platelet rich plasma |
| ES2221770B2 (es) | 2002-04-19 | 2006-07-16 | Eduardo Anitua Aldecoa | Metodo de preparacion de un compuesto para la regeneracion de tejidos. |
| US20060004189A1 (en) * | 2004-07-02 | 2006-01-05 | James Gandy | Compositions for treating wounds and processes for their preparation |
| AU2006282799B2 (en) * | 2005-08-26 | 2012-11-29 | Healthpartners Research & Education | Methods for treatment of headaches by administration of oxytocin |
| US9808509B2 (en) * | 2007-06-08 | 2017-11-07 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| AU2008297889A1 (en) * | 2007-09-14 | 2009-03-19 | Formycon Ag | Use of SLIT, nephrin, ephrin or semaphorin for treatment of cartilage diseases |
| PL2430977T3 (pl) | 2009-05-14 | 2020-08-24 | Biotechnology Institute, I Mas D, S.L. | Sposób preparowania co najmniej jednego związku z krwi i urządzenie do pobierania próbek do stosowania podczas realizacji wspomnianego sposobu |
| KR101114712B1 (ko) * | 2009-10-23 | 2012-02-29 | 세원셀론텍(주) | 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법 |
| ES2369945B1 (es) | 2011-07-29 | 2012-10-15 | Eduardo Anitua Aldecoa | Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento. |
-
2012
- 2012-08-09 ES ES201200810A patent/ES2442242B1/es not_active Expired - Fee Related
-
2013
- 2013-07-19 JP JP2015525915A patent/JP6339568B2/ja not_active Expired - Fee Related
- 2013-07-19 ES ES13756518.0T patent/ES2662385T3/es active Active
- 2013-07-19 MX MX2015001677A patent/MX357828B/es active IP Right Grant
- 2013-07-19 TW TW102125858A patent/TWI649084B/zh not_active IP Right Cessation
- 2013-07-19 KR KR1020157001551A patent/KR102149162B1/ko not_active Expired - Fee Related
- 2013-07-19 RU RU2015104076A patent/RU2696497C2/ru active
- 2013-07-19 CN CN201380041280.4A patent/CN104519961A/zh active Pending
- 2013-07-19 WO PCT/ES2013/000176 patent/WO2014023860A1/es not_active Ceased
- 2013-07-19 CA CA2881075A patent/CA2881075A1/en not_active Abandoned
- 2013-07-19 BR BR112015002760A patent/BR112015002760A2/pt not_active Application Discontinuation
- 2013-07-19 PE PE2015000116A patent/PE20150616A1/es not_active Application Discontinuation
- 2013-07-19 EP EP13756518.0A patent/EP2883569B1/en not_active Not-in-force
- 2013-08-08 AR ARP130102835A patent/AR092086A1/es unknown
- 2013-08-08 US US13/962,340 patent/US20140044795A1/en not_active Abandoned
-
2014
- 2014-12-23 CL CL2014003510A patent/CL2014003510A1/es unknown
- 2014-12-31 IN IN2675MUN2014 patent/IN2014MN02675A/en unknown
-
2015
- 2015-01-20 CO CO15010369A patent/CO7170177A2/es unknown
-
2016
- 2016-03-08 US US15/063,969 patent/US20160184360A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569204B1 (en) * | 1999-01-26 | 2003-05-27 | Eduardo Anitua Aldecoa | Bone tissue regenerating composition |
| US20090035382A1 (en) * | 2007-08-02 | 2009-02-05 | Biotechnology Institute, I Masd, S.L. | Method and compound for the treatment of articular diseases or articular pain, or for the treatment of skin for aesthetic or other purposes, and the method of preparation of the compound |
Non-Patent Citations (3)
| Title |
|---|
| 【基礎醫學與臨床】,2002. 22(3),193-199 |
| 藥學學報 2001, 36(8):636-640 |
| 藥學學報 2001, 36(8):636-640 【基礎醫學與臨床】,2002. 22(3),193-199 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2442242A1 (es) | 2014-02-10 |
| MX357828B (es) | 2018-07-25 |
| AR092086A1 (es) | 2015-03-25 |
| KR20150040860A (ko) | 2015-04-15 |
| MX2015001677A (es) | 2015-04-10 |
| CL2014003510A1 (es) | 2015-05-04 |
| KR102149162B1 (ko) | 2020-08-31 |
| EP2883569A1 (en) | 2015-06-17 |
| ES2662385T3 (es) | 2018-04-06 |
| TW201408310A (zh) | 2014-03-01 |
| EP2883569B1 (en) | 2017-12-20 |
| US20160184360A1 (en) | 2016-06-30 |
| RU2015104076A (ru) | 2016-09-27 |
| CA2881075A1 (en) | 2014-02-13 |
| CN104519961A (zh) | 2015-04-15 |
| US20140044795A1 (en) | 2014-02-13 |
| IN2014MN02675A (enExample) | 2015-08-28 |
| RU2696497C2 (ru) | 2019-08-02 |
| JP6339568B2 (ja) | 2018-06-06 |
| WO2014023860A1 (es) | 2014-02-13 |
| ES2442242B1 (es) | 2014-11-25 |
| PE20150616A1 (es) | 2015-05-25 |
| CO7170177A2 (es) | 2015-01-28 |
| BR112015002760A2 (pt) | 2020-04-22 |
| JP2015524464A (ja) | 2015-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117899111A (zh) | 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案 | |
| US11260101B2 (en) | Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof | |
| CN108503690A (zh) | 一种促进创伤后组织修复与再生的修复肽及其应用 | |
| M. Corbett et al. | Increasing neurogenesis with fluoxetine, simvastatin and ascorbic acid leads to functional recovery in ischemic stroke | |
| Park et al. | Distribution of human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs) in canines after intracerebroventricular injection | |
| Zhou et al. | Transcranial direct current stimulation alleviated ischemic stroke induced injury involving the BDNF-TrkB signaling axis in rats | |
| TWI649084B (zh) | 用於阿茲海默症之鼻內治療的具有生長因子之組成物之用途 | |
| TWI327473B (en) | Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin | |
| Humpel | NGF Released from Blood Cells or Collagen Hydrogels as a Therapeutic Target in Alzheimer’s Disease? | |
| JP2022545973A (ja) | 神経障害および精神障害の治療に使用するための神経毒素組成物 | |
| JP2023517602A (ja) | 心血管障害を処置することにおける使用のための神経毒素組成物 | |
| IT201600112420A1 (it) | Nuova formulazione per via intranasale | |
| CN106139125A (zh) | 白细胞介素4在制备促进急性脑损伤后神经功能恢复药物中的用途 | |
| WO2022104263A1 (en) | Secretome fractions and uses thereof | |
| Hesse | 11 Surgical Treatments | |
| CN114617865B (zh) | 乙酰左旋肉碱在制备用于预防或治疗静脉流出障碍性疾病的药物中的应用 | |
| PYRAMIDAL | Susana Valero Freitag | |
| Amirazodi | Emerging Therapies for Neurodegenerative Disorders like Alzheimer’s and Parkinson’s, EJCMPR. 2025; 4 (1): 309-329 | |
| Han et al. | Improved Regenerative Responses of Injured Spinal Cord Nerve Fibers by the Treatment of Sukjihwang (Rehmanniae radix preparat) | |
| Maniaci et al. | Platelet-Rich Plasma (PRP) in the Treatment of Long COVID Olfactory Disorders: A Comprehensive Review. Biomedicines 2024, 12, 808 | |
| Kadam et al. | Novel interventions for Alzheimer's disease | |
| Giarratana | The effects of genetic polymorphisms on recovery after repeated mild traumatic brain injury in a mouse model and personalized treatment approaches | |
| KR20230117190A (ko) | Pten 억제제에 의한 척수 손상의 치료 | |
| RU2572721C1 (ru) | Способ моделирования экспериментального амилоидоза у животных | |
| Ishii et al. | The Effect of One-sided Attenuation of Masseter Contraction on Maxillofacial Symmetry in Growing Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |